Orlando, FL (PRWEB) December 05, 2012
The Drug Risk Resource Center, a patient awareness group, is alerting women who were prescribed the birth control Yaz or Yasmin that Bayer has begun settling claims for certain patient injuries. However, only certain cases may qualify and the time to file is limited.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.
Bayer’s 3rd Quarter financial report shows the German drug maker has resolved nearly 3,500 Yaz lawsuit injury claims to date for a total cost of nearly $750 million, or an average of approximately $214,000 per case.*
The company also confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.
The settlement news comes as the American College of Obstetricians and Gynecologists renewed warnings recently that birth control pills containing drospirenone such as Yaz and Yasmin may have a higher risk of causing blood clots.**
Due to the number of patients filing claims, cases were consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism and believes it may be due to taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.
The Drug Risk Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012
**Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”